They don’t need to match existing, slightly lower efficacy but significantly better safety profile can still lead to approval because it’s an aggregate outcome that matters not just how effective the drug is in isolation.
BOT is a one, two punch I think, similar or better efficacy plus significantly lower side effects, still early days but shaping up to be a home run for the patient.
BOT, page-158
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
